REO 019, NCT02514382: Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma |
|
|
| Completed | 1b | 14 | US | Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus, Reolysin | University of Southern California, National Cancer Institute (NCI), Oncolytics Biotech | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | 04/22 | 04/22 | | |
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma |
|
|
| Completed | 1 | 23 | US | Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus | Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH) | Recurrent Plasma Cell Myeloma | 10/22 | 10/22 | | |
